74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Merus NV
Closed
SectorHealthcare
44.25 5.68
Overview
Share price change
24h
Min
41.56
Max
44.3
Income | -31M |
|---|---|
Sales | 9.1M |
EPS | -0.49 |
Profit margin | -338.326 |
Employees | 260 |
EBITDA | -88M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +113.77% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | 354M 3B |
|---|---|
Previous open | 38.57 |
Previous close | 44.25 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Merus NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Merus NV Forecast
Price Target
By TipRanks
113.77% upside
12 Months Forecast
Average 89.42 USD 113.77%
High 110 USD
Low 67 USD
Based on 15 Wall Street analysts offering 12 month price targets forMerus NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
